Teva fined €462.6M over Copaxone patent and competition allegationsnews2024-10-31T19:25:03+00:00October 31st, 2024|Endpoints News|
Federal court backs FDA approval of Jazz sleep drug competitornews2024-10-31T19:16:47+00:00October 31st, 2024|Endpoints News|
Regeneron prepares to compete with Eylea biosimilar from Amgennews2024-10-31T18:46:31+00:00October 31st, 2024|Endpoints News|
Gardasil demand in China sinks, and Merck expects the same next quarternews2024-10-31T17:33:18+00:00October 31st, 2024|Endpoints News|
Takeda says multiyear restructuring is ‘on track’news2024-10-31T15:21:41+00:00October 31st, 2024|Endpoints News|
Argenx reports Vyvgart sales streak, bolstered by launch in rare neuro disordernews2024-10-31T15:18:29+00:00October 31st, 2024|Endpoints News|
AbbVie adds to T cell engager momentum, with EvolveImmune pact starting at $65Mnews2024-10-31T12:00:02+00:00October 31st, 2024|Endpoints News|
Bristol Myers ups revenue guidance again, raising confidence in cost-cuttingnews2024-10-31T10:59:25+00:00October 31st, 2024|Endpoints News|
AbbVie’s immunology blockbusters make up for Humira sales drop in Q3news2024-10-30T18:10:20+00:00October 30th, 2024|Endpoints News|
Biogen seeks growth from pipeline as investors show signs of impatiencenews2024-10-30T17:11:27+00:00October 30th, 2024|Endpoints News|
